Trials in Thrombectomy for Acute Ischemic Stroke: Describing the State of Clinical Research in the Field

Abstract Background Endovascular thrombectomy has revolutionized treatment of ischemic stroke. Given the clinical and socioeconomic support for thrombectomy, new devices, procedures, and pharmaceuticals have emerged in recent years, and have been subject to a growing number of clinical trials worldwide. Objective To define the current state of thrombectomy clinical trials, highlight recent trends, and help guide future research in this area. Methods Current and previous clinical trials involving thrombectomy for ischemic stroke were queried from the Clinicaltrials.gov database. Trials were categorized by their current status, study design, funding type, exclusion criteria, study phase, enrollment, start and completion dates, country of origin, item of investigation, outcome metrics, and whether a peer-reviewed publication was linked to the trial. Results Querying the ClinicalTrials.gov registry yielded 196 trials, of which 161 (82.1%) were started within the past 5 years. The average time to completion was 30.6 months. A total of 62 studies (31.6%) examined the safety or efficacy of a thrombectomy device, 29 (14.8%) investigated a pharmacological intervention alone or in combination with a device, 59 (30.1%) examined aspects of the endovascular procedure on patient outcomes, and 14 (7.2%) examined diagnostic utility during thrombectomy. Most trials were funded by academic centers (53.1%) or industry (34.7%). Although the United States contributed the most studies overall (59; 30.1%), studies from European and Asian countries have been increasing since 2015. Conclusion These trends indicate an increasing number of trials starting the past few years, with most occurring in Europe and examining devices or aspects of the thrombectomy procedure.